Skip to content

The validation study of diagnostic performance of a novel serum biomarker for gastric cancer measured by ELISA; a multi-institutional prospective observational study

The validation study of diagnostic performance of a novel serum biomarker for gastric cancer measured by ELISA; a multi-institutional prospective observational study - The validation study of diagnostic performance of a novel serum biomarker for gastric cancer measured by ELISA; a multi-institutional prospective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000053203
Enrollment
500
Registered
2023-12-25
Start date
2023-12-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

None listed

Sponsors

Nagoya University Graduate School of Medicine
Lead Sponsor
1. Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine 2. Department of Family Medicine, Seoul National University Hospital, Seoul National University College of Medicine 3. Department of Surgery, Seoul National University Bundang Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ?Patients with histologically confirmed adenocarcinoma of the stomach, or healthy volunteers (individuals who received health care examination through department of family medicine and are confirmed to have no malignancies by upper GI endoscopy and abdominal CT scan) for a control group ?Aged over 20 years old ?No prior treatment (as for patients with gastric cancer) ?Written informed consent before initiation of study related procedures

Exclusion criteria

Exclusion criteria: ?Presence of other malignancies ?Any condition that makes the patient unsuitable for inclusion in the study according to the investigators

Design outcomes

Primary

MeasureTime frame
Serum SDF4 levels before treatment

Secondary

MeasureTime frame
Changes in serum SDF4 levels after treatment, comparison with the healthy control group, correlations with tumor factors, existing tumor markers, inflammatory factors and postoperative outcomes

Countries

Japan,Asia(except Japan)

Contacts

Public ContactTakahiro Shinozuka

Nagoya University Graduate School of Medicine Department of Gastroenterological Surgery

tshinozuka@med.nagoya-u.ac.jp052-744-2249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026